

23 May 2021 |

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast episode of Five Must-Know Things, hear about GSK coming under pressure from investors; BMS focusing on a promising oncology target in a new deal; Sanofi's COVID-19 vaccine challenges; China's progress with mRNA coronavirus vaccines; and new headwinds for Pfizer's Ibrance.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 21 May 2021, including: GSK comes under pressure from investors; BMS focuses on a promising oncology target in a new deal; Sanofi's COVID-19 vaccine faces challenges; China progresses its mRNA expertise for new coronavirus vaccines; and Pfizer's Ibrance faces new headwinds.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Walmsley Under Pressure Over GSK's Strategy](#)" - Scrip, 19 May, 2021.)

(Also see "[Bristol Pays Out \\$200m For Agenus' Preclinical Bispecific TIGIT](#)" - Scrip, 18 May, 2021.)

(Also see "[Sanofi Sees Booster Role For Covid Vaccine After Solid But Underwhelming Results](#)" - Scrip, 17 May, 2021.)

(Also see "[How A Small Chinese Biotech Is Taking On mRNA Vaccine Giants](#)" - Scrip, 14 May, 2021.)

(Also see "[*CDK4/6 Market: Is A Shakeup Underway?*](#)" - Scrip, 13 May, 2021.)

[*Click here to explore this interactive content online*](#) ✎